PEGylated L-asparaginase
Disclosed is a conjugate of a protein having substantial L-asparagine amino hydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight of about 5000 Da and the protein is an L-asparaginase from Erwinia . The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.
1. A conjugate comprising four L-asparaginase monomers, each monomer having the amino acid sequence of SEQ ID NO: 1 and conjugated to polyethylene glycol (PEG) molecules, wherein each PEG molecule has a molecular weight of about 5000 Da, wherein each monomer further comprises accessible amino groups, and wherein about 100% of said accessible amino groups in the monomers are covalently linked to a PEG molecule.
2. The conjugate of claim 1 , wherein said PEG molecules are monomethoxy-polyethylene glycol.
3. The conjugate of claim 1 , wherein said conjugate has a longer in vivo half-life as compared to an Erwinia chrysanthemi L-asparaginase.
4. The conjugate of claim 1 , wherein said conjugate has increased residual enzymatic activity in vivo when compared to a conjugate of an Erwinia chrysanthemi L-asparaginase conjugated to at least one PEG molecule having a molecular weight of 10,000 Da.
5. The conjugate of claim 1 , wherein said conjugate has at least 75% in vitro activity compared to Erwinia chrysanthemi L-asparaginase.
6. The conjugate of claim 1 , wherein said conjugate has at least 80% in vitro activity compared to Erwinia chrysanthemi L-asparaginase.
7. The conjugate of claim 1 , wherein said conjugate has at least 85% in vitro activity compared to Erwinia chrysanthemi L-asparaginase not conjugated to PEG molecules.
8. The conjugate of claim 1 , wherein said conjugate elicits a lower immunogenic response in a patient compared to an Erwinia chrysanthemi L-asparaginase.
9. The conjugate of claim 1 , wherein said conjugate does not cross-react with antibodies to Escherichia coli L-asparaginase.
10. The conjugate of claim 1 , wherein said monomers are recombinant proteins.